📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 16:29
538 analysed today
FollowTelegram
538
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
50.6% Revenue Growth in Q1 FY27; Coris Acquisition Impacts Consolidated Margins
3B BlackBio Dx reported a consolidated revenue of ₹33.49 Cr for Q1 FY27, a 50.6% increase from ₹22.23 Cr in Q1 FY26. This growth was primarily driven by the inclusion of Coris BioConcept, which contributed ₹8.63 Cr to the top line. However, consolidated PAT declined 29% YoY to ₹8.98 Cr, as Coris reported a negative EBITDA of ₹3.52 Cr. The standalone Indian Molecular Diagnostics (MDx) business remains healthy, growing 17.4% YoY in revenue to ₹23.43 Cr with a PAT of ₹13.68 Cr.
Confidence: HIGH
What changedThe company has fully consolidated its acquisition of Coris BioConcept, leading to a significant top-line jump but temporary margin compression due to acquisition-related losses.
Why it mattersThe transition from a domestic qPCR player to a global diagnostics firm with NGS and Lateral Flow capabilities is underway, but the short-term financial profile is being impacted by integration costs and geopolitical export hurdles.
Consolidated Revenue (Q1 FY27): ₹33.49 CrCoris Revenue Contribution: ₹8.63 CrConsolidated PAT (Q1 FY27): ₹8.98 CrMDx Export Growth: 38.3%Reagent Rental Revenue Target: 20-25%
📅 Short termThe stock may face pressure due to the 29% YoY decline in consolidated PAT, despite the strong revenue growth, as the market digests the impact of the Coris acquisition.
📈 Long termThe company is structurally expanding its product portfolio (NGS, Lateral Flow) and global footprint (70+ countries), which could drive 15-20% growth if the Coris integration succeeds.
⚠ Risk flags
- Margin dilution from Coris BioConcept losses
- Geopolitical tensions affecting export orders
- Higher debtor levels due to liberal credit policy
Key Highlights
Consolidated revenue increased to ₹33.49 Cr in Q1 FY27 from ₹22.23 Cr in Q1 FY26
Coris BioConcept acquisition contributed ₹8.63 Cr to revenue but had a negative EBITDA of ₹3.52 Cr
Standalone MDx revenue (excluding Coris) grew 17.4% YoY to ₹23.43 Cr
Export sales for MDx reached ₹5.96 Cr in Q1 FY27 compared to ₹4.31 Cr in Q1 FY26
Company maintains a ~15% market share in the Indian Molecular Diagnostics industry valued at ₹500-600 Cr
👀 What to Watch
Investors should monitor the turnaround timeline for the Coris BioConcept acquisition and the impact of the company's 'liberal credit policy' on working capital and debtor levels.
50.6% Revenue growth for 3B BlackBio Dx in Q1; Consolidated PAT falls 29% to ₹8.98 Cr
3B BlackBio Dx reported a strong 50.6% YoY growth in consolidated revenue to ₹33.49 Cr for Q1 FY27. However, consolidated PAT declined by 29% YoY to ₹8.98 Cr, significantly impacted by a 384% surge in employee benefit expenses and a 188% rise in other expenses. A key observation is that standalone PAT (₹14.11 Cr) was substantially higher than consolidated PAT, indicating that international subsidiaries or recent acquisitions are currently operating at a loss.
Confidence: HIGH
What changedThe company has transitioned from a high-margin standalone operation to a consolidated entity with significantly higher fixed costs due to global expansion and regulatory compliance efforts.
Why it mattersWhile top-line growth is robust, the sharp margin compression suggests high 'burn' in international markets or integration challenges with the new acquisition, which could pressure short-term valuations.
Consolidated Revenue (Q1 FY27): ₹33.49 CrConsolidated PAT (Q1 FY27): ₹8.98 CrEmployee Cost Increase (YoY): 384%Standalone PAT: ₹14.11 CrQ1 Revenue vs TTM Revenue: ~23.6%
📅 Short termThe market is likely to react negatively to the significant PAT decline and the drag caused by subsidiaries, despite the healthy revenue growth.
📈 Long termThe long-term outlook depends on the company's ability to leverage its international footprint and IVDR certifications to capture higher-margin diagnostic markets globally.
⚠ Risk flags
- Subsidiary losses
- Sharp increase in fixed operating costs
- Integration risks of international acquisitions
Key Highlights
Consolidated Revenue from operations increased 50.6% YoY to ₹33.49 Cr from ₹22.23 Cr.
Consolidated PAT fell 29% YoY to ₹8.98 Cr compared to ₹12.64 Cr in the same quarter last year.
Employee benefit expenses surged to ₹8.55 Cr from ₹1.77 Cr YoY, reflecting expansion and integration costs.
Standalone PAT of ₹14.11 Cr outperformed the consolidated figure by ₹5.13 Cr, highlighting subsidiary-level drag.
Other expenses rose to ₹8.87 Cr, driven by IVDR regulatory registration costs and international trade fair participation.
👀 What to Watch
Investors should monitor the turnaround timeline for the international subsidiaries and the stabilization of operating margins as the Coris BioConcept acquisition is integrated.
₹33.49 Cr Q1 Revenue: 3B BlackBio Dx Reports 50.6% YoY Growth; Diagnostics Segment Up 60%
3B BlackBio Dx reported a strong 50.6% YoY growth in consolidated revenue to ₹33.49 Cr for Q1 FY27, primarily fueled by the Diagnostic Kits segment which reached ₹32.06 Cr. Despite the top-line surge, Consolidated Profit Before Tax (PBT) declined 16.6% YoY to ₹13.22 Cr, impacted by higher operational and regulatory costs related to IVDR registration. Standalone Net Profit showed a 13.2% increase to ₹14.11 Cr. The Agrochemicals business continues to shrink, contributing only ₹1.43 Cr to the top line as the company pivots toward molecular diagnostics.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, showing strong diagnostic growth but consolidated margin pressure due to regulatory and expansion costs.
Why it mattersConfirms the successful scale-up of the molecular diagnostics business (TRUPCR), which now dominates the revenue mix, though international expansion costs are currently impacting the consolidated bottom line.
Consolidated Revenue (Q1): ₹33.49 CrDiagnostic Segment Revenue: ₹32.06 CrConsolidated PBT: ₹13.22 CrStandalone Net Profit: ₹14.11 CrStandalone Other Expenses: ₹3.20 Cr
📅 Short termThe market may react to the strong top-line growth in diagnostics, though the decline in consolidated PBT might limit immediate upside.
📈 Long termThe transition to a high-margin diagnostics player is well underway, with the diagnostic segment generating almost all segment profits and driving international expansion.
⚠ Risk flags
- Regulatory compliance costs (IVDR)
- Declining agrochemical segment
- Subsidiary performance impacting consolidated margins
Key Highlights
Consolidated Revenue from operations rose to ₹33.49 Cr, a 50.6% increase from ₹22.23 Cr in Q1 FY26
Diagnostic Kits segment revenue grew 60.6% YoY to ₹32.06 Cr, now comprising 95.7% of total revenue
Consolidated PBT decreased to ₹13.22 Cr from ₹15.86 Cr in the same quarter last year
Standalone Other Expenses increased by 49.2% to ₹3.20 Cr, cited for IVDR registration and trade fairs
Agrochemical segment revenue fell 37% YoY to ₹1.43 Cr, reflecting the company's strategic pivot
👀 What to Watch
Monitor the impact of IVDR regulatory costs on margins in upcoming quarters and the scaling of the international business through the UK and Belgian subsidiaries.
